Otonomy (OTIC) Stock Price, News & Analysis

Company Overview

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Key Stats

• Today's Range: $0.0085 to $0.0085
• 50-Day Range: $0.01 to $0.12
• 52-Week Range: $0.01 to $2.54
• Volume: N/A
• Average Volume: 937,525 shs
• Market Capitalization: $582.48 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OTIC Stock Analysis - Frequently Asked Questions

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) posted its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19).

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Otonomy investors own include Trevena (TRVN), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Fortress Biotech (FBIO) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OTIC
• CIK: 1493566
• Web: www.otonomy.com
• Phone: (619) 323-2200
• Fax: 619-291-9190
• Employees: 51
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.18 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -137.86%
• Return on Assets: -68.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.74
• Quick Ratio: 1.74

Sales & Book Value

• Annual Sales: $130 thousand
• Price / Sales: 4.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.97 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 68,527,000
• Free Float: 67,780,000
• Market Cap: $582.48 thousand
• Optionable: Optionable
• Beta: 1.54